Benzoyl peroxide

The selected PanOxyl 4% and 10% washes and Rite Aid 10% gel are OTC acne treatments marketed under monograph M006, rather than individually approved Epsolay products. Their label instructions and vehicles differ. This reference excludes fixed combinations and other strengths/vehicles, which need separate package verification.

Epsolay 5% microencapsulated cream is approved for inflammatory rosacea lesions in adults; its rosacea regimen cannot be assigned to an ordinary OTC acne wash. The AAD 2024 public guideline summary strongly recommends benzoyl peroxide for acne and advises combining topical/oral antibiotics with benzoyl peroxide to reduce resistance, while limiting oral-antibiotic use. This is acne guidance, not an Epsolay indication extension.

Apply only to the skin. The selected labels do not provide a numeric pediatric age cutoff or child-specific dose; do not import an age approval from a combination acne medicine. Reduce use for bothersome drying/peeling and stop for severe irritation.

Prime the pump until the first drop appears. On clean, dry skin apply a pea-sized amount in a thin layer to EACH facial area: forehead, chin, nose, and each cheek, once daily. Avoid eyes, lips, mouth, cuts, abrasions, eczema, and sunburn. Wash hands after application. Discard unused cream 60 days after first use; this is an adult rosacea regimen.

Epsolay formally contraindicates previous hypersensitivity to benzoyl peroxide or its components. The selected OTC labels direct against use with very sensitive skin or sensitivity to benzoyl peroxide; they do not use the prescription contraindications format. Check all inactive ingredients in the specific package.

None of the selected labels contains a boxed warning. FDA’s benzene testing led to limited product/lot recalls, not a blanket withdrawal of benzoyl peroxide or a new class boxed warning.

Expected local effects include dryness, burning/stinging, redness, itching, scaling, or swelling. Epsolay trials reported application-site pain, redness, itching, and edema; trial rates do not predict every individual response. Serious allergy requires immediate cessation and medical assessment. OTC labels direct immediate medical help or Poison Control after swallowing. Epsolay does not provide a numeric overdose/toxicity regimen; excessive use should prompt exposure and symptom assessment rather than an invented antidote.

Using another topical acne medicine simultaneously increases irritation/dryness according to the OTC labels. If irritation occurs, use one at a time and reassess the regimen. AAD supports combining therapeutic mechanisms and benzoyl peroxide with antibiotics, but this does not require applying every product together at the same time or exceeding package doses.

Epsolay’s selected label supplies no dedicated interaction-dose algorithm, and these product sources do not establish CYP, anticoagulant, or systemic-renal drug adjustments. Check the exact label of any retinoid, antibiotic, or fixed combination rather than assuming chemical compatibility or equivalent timing for all formulations.

PanOxyl directs professional consultation during pregnancy or breastfeeding. Epsolay systemic exposure has not been quantified; the label expects little fetal or nursing-infant exposure because absorbed peroxide becomes benzoic acid, but there are no direct milk/infant-effect data or product reproductive studies. Consider clinical need and breastfeeding benefits; these expectations are not proof of zero risk or an automatic recommendation for every formulation.

Epsolay pediatric rosacea safety/effectiveness are not established; its indication is adult. No overall geriatric difference was observed in its trials. The selected OTC labels have no numerical child age/dose band; clinician assessment is appropriate before treating young children rather than extrapolating adult acne self-treatment.

Selected product labels do not establish renal/hepatic dose adjustments or impairment-specific studies. Absorbed benzoyl peroxide is converted in skin to benzoic acid and eliminated in urine; this does not justify a numeric kidney adjustment or a claim of established safety in every impairment.

Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic actions. AAD identifies reduction of acne-associated skin bacteria as a treatment rationale. Epsolay’s precise rosacea mechanism and pharmacodynamics are unknown; its silicon-dioxide microcapsules define a particular formulation, not equivalence to unencapsulated acne gel.

Drug absorbed through skin becomes benzoic acid and is excreted in urine. Epsolay systemic exposure was not assessed; no reliable product-specific half-life or bioavailability is supplied here. Its vehicle-controlled adult rosacea studies support its labeled indication, not a broad assertion that every benzoyl-peroxide product treats rosacea.

Check diagnosis, lesion response, application amount/frequency, dryness, dermatitis, and adherence. Reassess severe irritation, allergic symptoms, sunburn, or treatment failure; an OTC label without scheduled laboratory tests is not a reason to invent routine serum monitoring. Review all concurrent acne products and any antibiotic course. FDA’s March 2025 testing found elevated benzene in a minority of tested products and prompted specific retail-level recalls; verify the actual product/lot and discard expired products.

Use only on skin, follow wash-versus-leave-on instructions, avoid eyes/lips/mouth, and protect clothing/hair from bleaching. Wash hands after Epsolay and keep its non-child-resistant pump away from children. Stop serious hypersensitivity immediately and seek medical attention. Apply sun protection and do not escalate irritation-producing applications in pursuit of faster improvement.

Crown PanOxyl: 4% creamy wash in a 170 g tube and 10% foaming wash in a 156 g tube. Rite Aid Ryshi/daylogic 10% gel is a 28 g tube in the selected current SPL. Mayne Epsolay 5% is a white/off-white microencapsulated cream in a 30 g airless pump, NDC 51862-772-30, NDA214510. OTC source records identify monograph M006 status, not individual NDA approval. Appearance is not sufficient to authenticate a product.

Selected products: 4% creamy wash, 10% foaming wash, 10% leave-on gel, and 5% Epsolay cream containing 50 mg/g. Other marketed strengths and fixed combinations are outside this verified product set. Do not substitute a wash or ordinary 5% cream for Epsolay’s adult rosacea regimen based on concentration alone.

PanOxyl: 20–25°C. Epsolay: 20–25°C with 15–30°C excursions, keep away from heat, do not freeze, discard 60 days after first use. The selected Rite Aid gel Drug Facts does not supply a numeric storage range; follow its actual package/manufacturer instructions rather than borrowing Epsolay storage. Check expiration and applicable lot-specific recall instructions.